CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Atorvastatin calciumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00024531
NCT00024531Phase 2Completed
CompareCT.gov

Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease

Institute for the Study of Aging (ISOA)·interventional·Posted Sep 20, 2001·Updated Nov 9, 2006

In Brief

A Phase 2 clinical trial evaluating Atorvastatin calcium for Alzheimer Disease. Completed, across 1 site.

Detailed Summary

The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2001
Enrollment StartOct 1, 2000
Study CompletionAug 1, 2004
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Atorvastatin calciumdrug